B+
Bull case
20%
Probability
Target price
$54.74
Analysis reference price unavailable
Analysis 2025-09-29 · RankAlpha Sentiment AI
KNSA
Kiniksa InternationalFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$36.49
Analysis reference price unavailable
Analysis 2025-09-29 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$18.25
Analysis reference price unavailable
Analysis 2025-09-29 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-09-29
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market tone is cautious-to-neutral: short-term focus centers on near-term filings and trial readouts while longer-term interest depends on BD activity and cash runway [#PR], [#10-Q]. Recent price action shows elevated volatility consistent with small-cap biotech peers when binary clinical events are pending [#yfinance].
RankAlpha Sentiment AI - 2025-09-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly financial report / 10-Q / 8-K corporate updateHigh impact
Quarterly results and management commentary on cash runway, R&D milestones, and business-development progress; SEC filings and company press release are primary sources [#10-Q], [#PR].
-catalystTopline clinical readouts from pipeline studiesHigh impact
Efficacy/safety toplines from pivotal/phase 2b studies could cause binary moves depending on outcomes and labeling implications; monitor clinicaltrials.gov and company PRs [#NCT], [#PR].
-catalystBusiness development / licensing dealsHigh impact
Partnerships or out-licensing of assets would materially de-risk programs and often re-rate small-cap biotechs over multiple quarters [#PR].
Recommendation
N/A
No formal recommendation provided.
As of 2025-09-29 • Updated nightlySource: Internal modelMethodology